Research progress of PARP1 in colorectal cancer
10.3872/j.issn.1007-385x.2019.12.017
- VernacularTitle:聚ADP核糖聚合酶在结直肠癌中作用的研究进展
- Author:
LI Jingjing
1
;
SUN Qi
2
;
LIU Bin
3
Author Information
1. Department of Pathology and Pathophysiology, School of basic Medicine, Gansu University of traditional Chinese Medicine,Pathology Department of the 940th Hospital of the Joint Service support Force of the people's Liberation Army
2. Pathology and Disease of basic Medical College of Lanzhou University
3. Pathology Department of the 940th Hospital of the Joint Service support Force of the people's Liberation Army
- Publication Type:Review
- Keywords:
聚ADP核糖聚合酶（PARP）；结直肠癌（CRC）；PARP抑制剂（PARPi）；合成致死；放疗与化疗
- From:
Chinese Journal of Cancer Biotherapy
2019;26(12):1400-1404
- CountryChina
- Language:Chinese
-
Abstract:
近年来 DNA修复途径成为癌症治疗的热门靶点， 聚ADP核糖聚合酶［poly（ADP）-ribosepolymerase，PARP]作为DNA修 复的关键酶得到了广泛研究，目前上市的PARP抑制剂（PARP inhibitor，PARPi）药物，在乳腺及卵巢等肿瘤中取得了革命性的突 破。结直肠癌（CRC）具有异质性，其发生与发展是一个多途径、多基因参与及多步骤的过程，其发病率与病死率在中国逐年上 升。研究发现，PARP1与CRC的发生、发展及治疗密切相关，本文从PARP1的分子结构及生物学功能、PARPi的作用机制、PARP1 在CRC组织中的表达情况、PARP1与结直肠癌干细胞的关系、PARPi与CRC治疗的关系等5个方面对PARPi在CRC中作用的研 究进展作一系统综述，为临床治疗CRC寻找新的治疗策略。
- Full text:20191217.pdf
